Utrecht, 24.06.2020 – Despite the restrictions of Covid-19, the GNA NOW Consortium enjoyed a successful first annual meeting on Wednesday 24 June. Held online, the half-day meeting brought together 29 Consortium members to discuss the results achieved to date and the plans for the upcoming year.The meeting got underway with an introduction from new project lead, Eric Bacqué (Evotec). This was followed by presentations from the various work package leads, with time built in for discussion between each presentation. Updates were also given on all of the project drug development platforms, data infrastructure, patient and public involvement, the activities of the Incubator Management Office, and the impacts of the Covid-19 crisis. The meeting ended with an overview of the ongoing communication and dissemination plans.
Commenting on the meeting, Kristina Orrling, GNA NOW Program Manager at Lygature said: “A year into the project, I’m delighted to see all three programmes progressing well. Thanks to clever teamwork and well-planned mitigation measures, the consortium has handled the Covid-19 situation in an exemplary way. While I missed the informal discussions of a face-to-face meeting, which often spark the really innovative ideas, the online meeting was a success – providing a comprehensive overview of project developments over the last year.”
About GNA NOW
Established in July 2019, the GNA NOW Consortium is a European collaboration of 11 partners focused on progressing Gram-Negative antibiotics from lead optimization to the completion of Phase I trials. Working under the AMR Accelerator umbrella, the project is funded by the Innovative Medicines Initiative (IMI) with in-kind contributions from industry partner, Evotec.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853979. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the views of the GNA NOW Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Kristina Orrling, Lygature: email@example.com
Dr. Sophie Lagrange, Evotec: Sophie.firstname.lastname@example.org